Simon Baldacci
YOU?
Author Swipe
View article: Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors Open
Antibody-based therapies have revolutionized cancer treatment but have several limitations. These include downregulation of the target antigen, mutation of the target epitope, and, in the case of antibody–drug conjugates (ADC), resistance …
View article: Eradicating Drug-tolerant Persister Cells in <i>EGFR-</i> Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Eradicating Drug-tolerant Persister Cells in <i>EGFR-</i> Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy Open
EGFR tyrosine kinase inhibitors have dramatically improved outcomes for patients with EGFR-mutated non–small cell lung cancer (NSCLC), but relapse frequently occurs because of drug-tolerant persister (DTP) cells that can evolve and develop…
View article: Data from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Data from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumo…
View article: Supplementary Figures S1-S9 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Supplementary Figures S1-S9 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Supplementary Figure 1. Identification of MET rearrangement cases in the DFCI and GRCC cohorts. Supplementary Figure 2. Genomic features of MET rearrangements. Supplementary Figure 3. Oncoprint of likely oncogenic MET rearrangements and of…
View article: Supplementary Tables S1-S6 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Supplementary Tables S1-S6 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Supplementary Table 1. Clinical characteristics of patients with MET rearrangement-positive tumors in the DFCI/GRCC clinicopathologic cohort. Supplementary Table 2. Clinical characteristics of patients with MET fusion-positive tumors in th…
View article: Supplementary Methods from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Supplementary Methods from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Supplementary Methods
View article: Supplementary Appendix from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Supplementary Appendix from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Clinical trial protocol
View article: Supplementary Figure 14 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Figure 14 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Western blot analysis of MET and ERK1/2 phosphorylation in MET R1170Q cell models. MET and ERK1/2 phosphorylation in (A) Ba/F3 cells stably transduced with MET R1170Q and (B) 293T cells transiently overexpressing MET R1170Q. Cells were tre…
View article: Supplementary Table 4 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 4 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
List of missense mutations with unknown biologic function and their pathogenicity scores using all three in silico tools in cohort #1
View article: Supplementary Table 6 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 6 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Prevalence of MET tyrosine kinase domain (TKD) mutations across cancer types in cohort #1.
View article: Supplementary Table 10 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 10 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Characteristics of 44 NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations in cohort #1.
View article: Supplementary Table 13 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 13 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Concurrent driver mutations according to oncogenic / likely oncogenic MET TKD mutations detected in cohort #2.
View article: Supplementary Table 22 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 22 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Oncogenic / likely oncogenic MET TKD mutations in RCC compared to those detected in NSCLC in cohort #1.
View article: Supplementary Figure 10 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Figure 10 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
MET TKD mutations in NSCLC cohort of Caris Life Sciences. (A) Flowchart of the NSCLC subgroup in the Caris Life Sciences dataset. (B) Prevalence of MET TKD mutations in NSCLC cases in the Caris Life Sciences dataset (MET TKD mutations in 2…
View article: Data from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Data from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic in a subset of papillary renal cell carcinomas. Here, using comprehensive genomic profiling among >600,000 patients, we identify activating MET TKD point muta…
View article: Supplementary Table 6 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 6 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Prevalence of MET tyrosine kinase domain (TKD) mutations across cancer types in cohort #1.
View article: Supplementary Table 14 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 14 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Concurrent genomic drivers in cases with oncogenic / likely oncogenic MET tyrosine kinase domain (TKD) mutations and co-occurring MET gene amplification in cohort #2.
View article: Supplementary Figure 19 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Figure 19 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Equilibration of interactions that drives ATP affinity in the presence MET F1200I mutant. (A) Representative structure of ATP bound MET F1200I with the regions of interest highlighted [alpha C helix (red), DFG site (green), mutation site (…
View article: Supplementary Table 11 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 11 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Detailed genomic characteristics for each case of NSCLC with oncogenic / likely oncogenic MET tyrosine kinase domain (TKD) mutations in cohort #1.
View article: Supplementary Table 16 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 16 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Comparison between clinicopathologic characteristic of NSCLCs with oncogenic / likely oncogenic MET tyrosine kinase domain (TKD) mutations without concurrent other drivers to NSCLCs with MET exon 14 alterations in cohort #2.
View article: Supplementary Table 8 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 8 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Prevalence of MET tyrosine kinase domain (TKD) mutations across cancer types in cohort #2.
View article: Supplementary Table 9 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 9 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Prevalence of MET tyrosine kinase domain (TKD) mutations across tumor in “other cancers” from Supplementary Table 8.
View article: Supplementary Table 5 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 5 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
List of missense mutations with unknown biologic function and their pathogenicity scores using all three in silico tools in cohorts #2
View article: Supplementary Figure 10 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Figure 10 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
MET TKD mutations in NSCLC cohort of Caris Life Sciences. (A) Flowchart of the NSCLC subgroup in the Caris Life Sciences dataset. (B) Prevalence of MET TKD mutations in NSCLC cases in the Caris Life Sciences dataset (MET TKD mutations in 2…
View article: Supplementary Figure 9 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Figure 9 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Genomic characterization of NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations in cohort #2. (A) Oncoprint summarizing the genomic profile and (B) the TMB value of the 78 NSCLC cases with oncogenic / likely oncogenic MET …
View article: Supplementary Figure 12 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Figure 12 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Sensitivity pattern of MET TKD mutations in 293T cells. (A) ERK-mediated transcriptional activation assessed by luciferase assay in 293T cells co-transfected with MET WT or TKD mutant constructs, an ERK activation reporter vector (pGL4.33)…
View article: Supplementary Table 19 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 19 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Detailed clinicopathologic and genomic characteristics related to renal cell cancer cases in cohort #1.
View article: Supplementary Figure 5 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Figure 5 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Prevalence of MET TKD mutation in various cancer types according to OncoKB status in each dataset in cohort #1.
View article: Supplementary Table 7 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Supplementary Table 7 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Open
Prevalence of MET tyrosine kinase domain (TKD) mutations among “other cancers” from Supplementary Table 6.